EDMONTON, AB — January 14, 2026 — Leads & Copy — Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), a global medical cannabis company based in Canada, has announced significant progress in its powdery mildew (PM) resistance research, nearly a year after discovering a novel source of genetic resistance against powdery mildew, PM2.
Since the initial discovery, Aurora has conducted multiple rounds of crosses to transfer PM2 resistance into elite breeding lines. Testing in breeding populations is done through controlled infection trials with high disease pressure to validate the durability and effectiveness of PM2 resistance. These trials ensure disease resistance is integrated into high-performing genetics without compromising quality traits for patients and consumers.
“By moving from research into production trials of cultivars with verified PM2 resistance at our Aurora Ridge manufacturing facility, we’re not only validating the science but also shaping the future of cannabis cultivation,” said Lana Culley, Vice President of Innovation and International Operations at Aurora. Culley added that this progress is a critical step toward commercializing powdery mildew-resistant cultivars, demonstrating how science-driven innovation adds value to the company’s global portfolio of proprietary cannabis products.
The company has shared its research at scientific and industry conferences, including the Plant & Animal Genome Conference, the Canadian Society for Horticultural Science & Canadian Society of Agronomy 2025 Conference, the 4th Annual Cannabis Scientific Symposium at the McGill Research Centre for Cannabis, and the PhotoX Conference.
The proprietary genetic marker technology behind PM2 was developed by scientists at Aurora Coast, with collaboration from researchers at the University of British Columbia and research funding from Genome British Columbia. If the production trials are successful, the company will look to commercialize PM-resistance cultivars later this year to protect plant health, reduce operational costs, and improve product quality.
Aurora continues to advance cannabis science through integrating breeding techniques with research, setting new standards for quality and efficiency, and building a production network to support markets.
The intellectual property is patent pending in Canada, the United States, Europe, Australia, New Zealand, and Israel.
Aurora is Opening the World to Cannabis™, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. The Company’s adult-use brand portfolio includes Drift®, San Raf®, Daily Special™, Tasty’s™, Being® and Greybeard®. Medical cannabis brands include MedReleaf®, CanniMed®, Aurora® and Whistler Medical Marijuana Co.®, as well as international brands, Pedanios®, IndiMed™ and CraftPlant™. Aurora also has a controlling interest in Bevo Farms Ltd., North America’s leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora’s brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched.
Aurora’s common shares trade on the NASDAQ and TSX under the symbol “ACB”.
Lana Culley, Vice President of Innovation and International Operations at Aurora, is the contact person mentioned in this press release.
Source: Aurora Cannabis Inc.
